Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The stock is in a well-established, long-term rising trend above the technical support level at 135.98 USD
Weaknesses
  • The company's earnings releases usually do not meet expectations.
  • With an enterprise value anticipated at 4.85 times the sales for the current fiscal year, the company turns out to be overvalued.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
JOHNSON & JOHNSON2.15%389 985
ROCHE HOLDING AG-3.61%289 019
PFIZER, INC.8.00%226 783
NOVARTIS AG-10.86%207 948
MERCK & CO., INC.-10.03%207 033
ABBVIE INC.18.58%185 357
NOVO NORDISK A/S8.79%158 090
BRISTOL-MYERS SQUIBB COMPAN..-3.75%140 511
ASTRAZENECA PLC4.34%138 967
AMGEN INC.-5.87%131 896
ELI LILLY AND COMPANY9.65%131 599
SANOFI-7.35%127 565
GLAXOSMITHKLINE PLC-21.66%92 552
CHUGAI PHARMACEUTICAL CO., ..47.95%77 766
JIANGSU HENGRUI MEDICINE CO..23.39%70 476
DAIICHI SANKYO COMPANY, LIM..45.72%67 763
More Results
Financials (USD)
Sales 2020 81 771 M - -
Net income 2020 15 967 M - -
Net Debt 2020 6 543 M - -
P/E ratio 2020 24,5x
Yield 2020 2,66%
Capitalization 392 B 392 B -
EV / Sales 2020 4,88x
EV / Sales 2021 4,42x
Nbr of Employees 132 200
Free-Float 84,3%
Upcoming event on JOHNSON & JOHNSON
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes